AML1-ETO t(8;21), Quantitative Test Cost & Procedure

Usage to find and measure RUNX1-RUNX1T1 fusions caused by t (8;21). Use to evaluate the risk of disease relapse and check for any minimally recurrent disease.

Quantitative identification of the t(8;21) RUNX1-RUNX1T1 fusion transcript using real-time RT-PCR (formerly called AML1-ETO). One tumour cell in 100,000 normal cells is the analytical sensitivity. Beneficial outcomes are presented as the ratio of (8;21) transcript levels to a normal control gene.

 Acute Myeloid Leukemia: What Is It?

Blood cancers that affect the bone marrow and blood cells include acute myeloid leukaemia.

The primary feature of this condition is the accelerated development of immature white blood cells (leucocytes), also referred to as leukemic blasts or myeloblasts. Anaemia, excessive bleeding, and bruising can also result from the bone marrow's inability to produce enough red blood cells and platelets. Acute myeloid leukaemia could be lethal.

Symptoms:

Acute myeloid leukaemia symptoms include:

• Shortness of breath
• an irregular heartbeat
• an increased risk of infection
• fever
• weight loss
• headaches
• drowsiness
• easy bruising

Why is this examination suggested?

To find the often-seen AML1-ETO t (8; 21) fusion transcript in the AML M2 subtype. This assay is intended to track the clinical course and efficacy of treatment for Minimal Residual Disease in addition to initial diagnosis and prognosis assessment (MRD). To anticipate an impending relapse, it may be helpful to track the disease's progression in the same patient. Clinical relevance

AML cases with the (8;21) translocation account for 5% of all topics. Often, these instances are categorised as core-binding factor AML (CBF-AML). In AML subtype M2, the translocation is typically linked to a high probability of complete remission and extended overall survival. For monitoring and diagnostic confirmation of minimum residual illness, this assay is advised (MRD).

Testing for c-KIT mutations could be considered. Few patients with acute myeloid leukaemia (AML) have the t(8;21) abnormality. The translocation can be identified as a standalone genetic anomaly or a component of more intricate monsters. The diagnosis of AML can be made based on the discovery of t(8;21) in a patient with bone marrow abnormalities. The prognosis is typically favourable for t(8;21).